Purchase Order 75N95023P00739
Award Date
9/8/23
Potential Completion Date
12/7/23
Potential Value
$20K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Reaction Biology Corporation
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $34,884 fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a small disadvantaged business, to conduct kinase inhibition testing on 100 novel small molecule compounds. The contract supports the work of the National Center for Advancing Translational Sciences (NCATS) within NIH, which is focused on developing potential anti-cancer agents. Reaction Biology will use its...
This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...
This is a $19,840.00 firm-fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for biochemical kinase assays on 160 compounds to determine their inhibitory activity against the kinases LATS1, LATS2, and AKT, which will inform the development of potential anti-cancer agents. This award was a...
This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The $102,100 contract is for testing 10 novel small molecule compounds against a panel of 50 wild-type kinases, as well as testing 5 compounds against a more comprehensive panel of 374 wild-type kinases. The purpose is to assess the kinase...
This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Reaction Biology Corporation, a small disadvantaged business contractor. The contract is for the testing of compounds for inhibition of 370 wild-type kinase enzymes, with a potential value of $166,500.00 and a completion date of December 6, 2022. Reaction Biology has previously provided kinase inhibition testing, cancer cell line...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $110,000.00 firm fixed price purchase order to Reaction Biology Corporation, a self-certified small disadvantaged business, for the testing of compounds to inhibit wild-type kinase enzymes. This requirement does not have a set-aside designation. Reaction Biology Corporation is a contract research organization that provides specialized bioassay testing and...
Reaction Biology Corporation was awarded a $16,480.80 firm fixed price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to test 35 novel small molecule compounds for inhibition of three wild-type kinase enzymes. Under the contract, Reaction Biology will utilize its Kinase HotSpot assay platform to test each compound at 10 different doses and provide one comprehensive report detailing results against the three kinases. The testing services...
This federal contract award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), was issued to Reaction Biology Corporation, a self-certified small disadvantaged business based in Malvern, PA. The $150,330 firm-fixed-price purchase order contract requires Reaction Biology to provide compound testing services, including screening 10 small molecule compounds against a panel of 50 kinases and 5 compounds against a panel of 374 kinases using the Kinase...